Adipotide (FTPP) Protocol Guide
Adipotide (FTPP, fat-targeted proapoptotic peptide) is a highly experimental peptidomimetic that targets prohibitin on the surface of blood vessels supplying white adipose tissue. The compound consists of a prohibitin-targeting sequence (CKGGRAKDC) linked to a proapoptotic peptide (D(KLAKLAK)2) that induces programmed cell death in adipose vasculature endothelial cells, cutting off blood supply to fat tissue and causing adipocyte death through ischemia. In rhesus monkey studies, Adipotide produced approximately 11% body weight loss and 38% reduction in abdominal fat in just 4 weeks. However, significant renal toxicity was observed, making comprehensive kidney monitoring mandatory. No human clinical trial data exists. This protocol covers conservative dosing, mandatory safety monitoring, and renal protection strategies.
Protocol Overview
- Compound
- Adipotide (FTPP / Fat-Targeted Proapoptotic Peptide)
- Category
- Experimental Fat Loss
- Mechanism
- Prohibitin-targeting peptide linked to proapoptotic domain; induces apoptosis in white adipose tissue vasculature
- Form
- Lyophilized powder (5mg vials)
- Route
- Subcutaneous
- Frequency
- Every other day (conservative)
- Cycle Length
- Maximum 4 weeks; 8+ week recovery
- Safety Level
- High risk - mandatory renal monitoring
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Ultra-Conservative | 0.25 mg/kg | Every other day | SubQ | 2 weeks |
| Conservative | 0.5 mg/kg | Every other day | SubQ | 4 weeks max |
| Primate Study Dose | 0.43 mg/kg | Daily | SubQ | 4 weeks |
Critical safety note: This is a highly experimental compound with NO human clinical trial data. Significant renal toxicity was observed in primate studies. Conservative every-other-day dosing is strongly recommended over daily administration. Mandatory renal function monitoring is required before, during, and after any protocol.
Reconstitution Guide
Standard Reconstitution
- Vial: 5mg Adipotide lyophilized powder
- Diluent: 1mL bacteriostatic water
- Concentration: 5mg/mL
- Example: 80kg subject at 0.5mg/kg = 40mg total (requires multiple vials)
Storage & Handling
- Pre-reconstitution: Freeze at -20°C
- Post-reconstitution: Refrigerate, use within 7 days
- Sensitivity: Peptide is sensitive to degradation
- Verify purity: COA with HPLC ≥98% essential
Expected Timeline
Side Effects & Monitoring
Known Side Effects (Primate Data)
- Renal toxicity (reversible proximal tubule changes)
- Proteinuria and elevated creatinine
- Dehydration / increased water intake
- Injection site reactions
- Possible electrolyte imbalances
Renal toxicity is the primary concern. Prohibitin is expressed on renal proximal tubule cells, making kidneys an off-target site.
Mandatory Precautions
- Baseline renal panel required before starting
- Weekly creatinine, BUN, eGFR, urinalysis
- Discontinue if creatinine rises >30% or proteinuria develops
- Maintain excellent hydration throughout
- No human safety data exists
- Contraindicated with pre-existing kidney disease
- Avoid nephrotoxic medications concurrently
Stacking Recommendations
Renal Protection Stack
- BPC-157: Renal protective and tissue repair properties
- NAC (N-acetyl cysteine): Renal antioxidant protection
- Adequate hydration: 3-4 liters water daily minimum
- Electrolytes: Monitor and supplement as needed
Avoid Combining With
- NSAIDs: Additional nephrotoxic burden
- Other experimental compounds: Cannot isolate adverse effects
- Nephrotoxic medications: Aminoglycosides, contrast dye, etc.
- High-dose creatine: May confound renal markers
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Renal Function | Creatinine, BUN, eGFR, cystatin C | Baseline, Weekly during, Week 2/4/8 post |
| Urinalysis | Microalbumin, protein, specific gravity | Baseline, Weekly during, Week 4/8 post |
| Electrolytes | Sodium, potassium, phosphate, calcium | Baseline, Weekly during |
| Body Composition | DEXA, abdominal MRI | Baseline, Week 4, Week 8 post |
Renal monitoring is non-negotiable. Weekly assessment during active use and continued monitoring for at least 8 weeks post-protocol. Cystatin C is a more sensitive early marker of kidney injury than creatinine.
Related Tools & Resources
